country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

製品番号: HY-183395

Copy Link Print Information

FPTI

FPTI is a SYT-SSX1 fusion protein modulator with selective cytotoxicity in SYT-SSX1-positive synovial sarcoma cells. FPTI down-regulates SYT-SSX1 expression and modulates its downstream target genes. FPTI induces apoptosis in synovial sarcoma cells. FPTI can be used for the research of synovial sarcoma.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号: 173374-58-8
分子式: C₁₅H₁₀FN₅
分子量:279.27

保管条件:

Please store the product under the recommended conditions in the Certificate of Analysis.

FPTI 構造式

CAS 番号: 173374-58-8

価格（税別）

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性

製品説明

体外実験

Anti-cancerCell Cycle RegulationApoptosis

Anti-cancer

FPTI (10-100 μM; 24-96 h) selectively reduces cell viability in SYT-SSX1-positive Yamato and ASKA synovial sarcoma cell lines with IC₅₀ values of 33 μM and 39 μM, respectively, while showing weaker activity against non-synovial sarcoma and normal cell lines^[1].

Anti-cancer

Cell Cycle Regulation

FPTI (10-40 μM; 72 h) modulates gene expression in SYT-SSX1-positive ASKA synovial sarcoma cells by downregulating SYT-SSX1 and key oncogenic downstream targets, while upregulating CDKN2A^[1].

Anti-cancer

Apoptosis

FPTI (10-40 μM; 24 h) induces apoptotic cell death in SYT-SSX1-positive ASKA synovial sarcoma cells in a concentration-dependent manner, with greater late-stage apoptosis observed at the 40 μM IC₅₀ dose after 24 h^[1].

Anti-cancer

Cell Cycle Regulation

Apoptosis

FPTI (10-40 μM; 72 h) induces G0-G1 cell cycle arrest and increases apoptotic sub-G0 cell population in SYT-SSX1-positive ASKA synovial sarcoma cells after 72 h, with the strongest effect observed at the 40 μM IC₅₀ dose^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

Yamato (SYT-SSX1-positive synovial sarcoma), ASKA (SYT-SSX1-positive synovial sarcoma), HEK293 (immortalized embryonic kidney), 143B (sarcoma), A673 (sarcoma)
Concentration:

10-100 μM (72 h); 40 μM (24, 48, 96 h)
Incubation Time:

24 h, 48 h, 72 h, 96 h
Result:

Reduced cell viability by 48.71% in HEK293, 67.35% in ASKA, and 72.48% in Yamato cells at 40 μM for 72 h compared to DMSO controls.
Showed insignificant cytotoxicity at 10 μM and 20 μM.
Induced cytotoxicity in HEK293 cells below 50% viability at 60, 80, 100 μM.
Showed no significant cytotoxicity in 143B or A673 cells.
Achieved IC₅₀ values of 39 μM for ASKA, 33 μM for Yamato, 66 μM for HEK293, 64 μM for 143B, and 70 μM for A673.

Real Time qPCR^[1]

Cell Line:

ASKA (SYT-SSX1-positive synovial sarcoma)
Concentration:

10 μM, 40 μM (72 h)
Incubation Time:

72 h
Result:

Downregulated expression of SYT-SSX1 and its downstream target genes cyclin D1 (CCDN1), β-catenin (CTNNB1), FZD, PDGFRA, COM1, SMARCB1, and P21 at 40 μM.
Induced dose-dependent repression of FZD, CCDN1, SMARCB1, and P21.
Downregulated EGFR and EGR1 only at 10 μM.
Upregulated CDKN2A with treatment.

Apoptosis Analysis^[1]

Cell Line:

ASKA (SYT-SSX1-positive synovial sarcoma)
Concentration:

10 μM (IC₁₀), 40 μM (IC₅₀) (24 h)
Incubation Time:

24 h
Result:

Altered cell forward and side scatter parameters compared to untreated cells.
Increased cell death to over twice the basal level at 10 μM.
Increased cell death to thrice the basal level at 40 μM.
Induced a marked increase in dual Annexin V/PI staining indicative of late apoptosis at 40 μM.

Cell Cycle Analysis^[1]

Cell Line:

ASKA (SYT-SSX1-positive synovial sarcoma)
Concentration:

10 μM (non-lethal dose), 40 μM (IC₅₀) (72 h)
Incubation Time:

72 h
Result:

Increased the sub-G0 cell population to 31.25% (from 5.385% in untreated cells) and reduced the G0-G1 population to 44.9% (from 69.1% in untreated cells) at 40 μM.
Left the S and G2/M phase populations nearly unchanged at 40 μM.
Increased the sub-G0 population to 15.3% and reduced the G0-G1 population to 53.5% at 10 μM.

Related Protocols :

化学情報

CAS 番号 173374-58-8
分子量 279.27
分子式 C₁₅H₁₀FN₅
SMILES

FC1=CC=C2NC=C(C2=C1)C3=NN=NN3C4=CC=CC=C4
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.

純度とドキュメンテーション

取扱説明書 (2659 KB)

参考文献

[1]. Natarajan V, et al. In silico and in vitro screening of small molecule Inhibitors against SYT-SSX1 fusion protein in synovial sarcoma. Computational biology and chemistry. 2018 Dec;77:36-43. [Content Brief]

Calculators

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

お問い合わせ在庫あり

Other size

お問い合わせ

Amount: USD 0.00

生物活性
- 製品説明
- 体外実験
化学情報
純度とドキュメンテーション
参考文献

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

FPTI

生物活性

製品説明

体外実験

化学情報

純度とドキュメンテーション

参考文献

Calculators

Help & FAQs

FPTI 関連分類

HY-183395 関連分類

Bioz

Keywords

最近チェックした製品